Holen Sie sich die Stockscreener-App
1.01
0.00%
0.00
Schlusskurs vom Vortag:
$1.01
Offen:
$1.0001
24-Stunden-Volumen:
9,958
Relative Volume:
0.06
Marktkapitalisierung:
$13.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.83M
KGV:
-1.3813
EPS:
-0.7312
Netto-Cashflow:
$-8.01M
1W Leistung:
-2.88%
1M Leistung:
+1.00%
6M Leistung:
-11.40%
1J Leistung:
-35.67%
1-Tages-Spanne:
$1.00
$1.03
1-Wochen-Bereich:
$0.9801
$1.05
52-Wochen-Spanne:
$0.8588
$2.67
Cocrystal Pharma Inc Stock (COCP) Company Profile
Firmenname
Cocrystal Pharma Inc
Sektor
Branche
Telefon
(786) 459-1831
Adresse
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.01 | 13.93M | 0 | -8.83M | -8.01M | -0.7312 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-07-08 | Eingeleitet | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Aktie (COCP) Neueste Nachrichten
What's Driving the Micro-Cap Mania in SKYQ and COCP - Kavout | AI
Price to book forward of Cocrystal Pharma Inc – FWB:8CC - TradingView
Cocrystal Pharma (COCP) Holds Near Key Support After Slight DeclinePCR Extreme - dars.gov.et
COCPCocrystal Pharma Inc Dividends - Finviz
Enterprise value to revenue forward of Cocrystal Pharma, Inc. – NASDAQ:COCP - TradingView
Price to earnings forward of Cocrystal Pharma, Inc. – NASDAQ:COCP - TradingView
Price to sales forward of Cocrystal Pharma, Inc. – NASDAQ:COCP - TradingView
Price to book forward of Cocrystal Pharma Inc – LS:A3DWYX - TradingView
Cocrystal Pharma Inc Actuals & Estimates (NASDAQ:COCP) - TradingView
Cocrystal Pharma(COCP) Stock Options Chain | Quotes & News - Moomoo
COCP Forecast — Price Target — Prediction for 2027 - TradingView
8CC Forecast — Price Target — Prediction for 2027 - TradingView
Cocrystal Pharma Inc (COCP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cocrystal Pharma Company Profile & Introduction - Moomoo
Cocrystal Pharma Inc (COCP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cocrystal Pharma Inc (COCP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cocrystal Pharma Inc (COCP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cocrystal Pharma Inc (COCP) Institutional Confidence - TradingKey
Cocrystal Pharma Inc (COCP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cocrystal Pharma Inc (COCP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cocrystal Pharma Inc (COCP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cocrystal Pharma Inc (COCP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cocrystal Pharma Appoints New CEO to Lead Transition - The Globe and Mail
Cocrystal Pharma Appoints James Sapirstein as New CEO – Leadership Transition and Company Details - Minichart
Cocrystal Pharma appoints James Sapirstein as CEO with new compensation package By Investing.com - Investing.com South Africa
Cocrystal Pharma appoints James Sapirstein as CEO with new compensation package - Investing.com India
James Sapirstein becomes CEO of Cocrystal Pharma (NASDAQ: COCP) - Stock Titan
COCP Q1 2026 Earnings: EPS Misses as Pre-Revenue Biotech Continues Development SpendingRetail Earnings Report - dars.gov.et
Cocrystal Pharma Appoints James Sapirstein as Chief Executive Officer - Moomoo
Cocrystal Pharma taps longtime biotech exec as its new CEO - The Business Journals
Cocrystal Pharma Inc. (COCP) Q1 2026 Earnings: Wider-than-expected Loss as R&D Pipeline ProgressesEarnings Whisper Number - newsline.com
Cocrystal Pharma (COCP) CEO awarded 235,000 stock options under 2025 plan - Stock Titan
Cocrystal Pharma (COCP) CEO James Sapirstein files initial Form 3 - Stock Titan
Cocrystal Pharma names James Sapirstein as CEO - The Pharma Letter
Cocrystal Pharma Inc. Announces CEO Changes - marketscreener.com
Cocrystal Pharma Names New CEO to Drive Antiviral Pipeline - TipRanks
Cocrystal Pharma names James Sapirstein as new CEO By Investing.com - Investing.com South Africa
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer - BioSpace
Cocrystal Pharma names James Sapirstein as new CEO - Investing.com
Veteran antiviral leader James Sapirstein to head Cocrystal Pharma (NASDAQ: COCP) - Stock Titan
Cocrystal Pharma Appoints James Sapirstein, Biopharma - GlobeNewswire
COCP: Presentation Highlights CDI-988 - Zacks Small Cap Research
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cocrystal Pharma (COCP) - The Globe and Mail
Noble Financial Maintains Cocrystal Pharma(COCP.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Cocrystal Pharma (COCP) proxy details board elections, pay and 2026 votes - Stock Titan
Cocrystal Pharma | 8-K: Current report - Moomoo
Cocrystal Pharma (COCP) Unveils Promising Antiviral Developments - GuruFocus
Cocrystal Pharma Reports Promising Pan-Viral Antiviral Activity - TipRanks
Cocrystal Pharma discovers new pan-viral inhibitors - BioWorld News
Cocrystal Pharma (NASDAQ: COCP) highlights pan-viral inhibitor data and Phase 1b progress - Stock Titan
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza - GlobeNewswire
Finanzdaten der Cocrystal Pharma Inc-Aktie (COCP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):